Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Short term Debt (2020 - 2022)

Anika Therapeutics (ANIK) has disclosed Short term Debt for 7 consecutive years, with $4.3 million as the latest value for Q2 2022.

  • Quarterly Short term Debt fell 74.42% to $4.3 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Jun 2022, down 74.42% year-over-year, with the annual reading at $4.3 million for FY2021, 67.04% down from the prior year.
  • Short term Debt for Q2 2022 was $4.3 million at Anika Therapeutics, roughly flat from $4.3 million in the prior quarter.
  • The five-year high for Short term Debt was $24.8 million in Q1 2021, with the low at $4.3 million in Q3 2021.
  • Average Short term Debt over 3 years is $10.3 million, with a median of $4.3 million recorded in 2021.
  • The sharpest move saw Short term Debt plummeted 67.04% in 2021, then plummeted 82.68% in 2022.
  • Over 3 years, Short term Debt stood at $13.1 million in 2020, then crashed by 67.04% to $4.3 million in 2021, then changed by 0.0% to $4.3 million in 2022.
  • According to Business Quant data, Short term Debt over the past three periods came in at $4.3 million, $4.3 million, and $4.3 million for Q2 2022, Q1 2022, and Q4 2021 respectively.